Living Liver Donor With Fasciola Hepatica: First Case Report in the Literature


AKBULUT A. S., ŞAHİN T. T., KOLU M., IŞIK B., BAYINDIR Y., YILMAZ S.

EXPERIMENTAL AND CLINICAL TRANSPLANTATION, cilt.19, sa.3, ss.276-279, 2021 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 19 Sayı: 3
  • Basım Tarihi: 2021
  • Doi Numarası: 10.6002/ect.2017.0318
  • Dergi Adı: EXPERIMENTAL AND CLINICAL TRANSPLANTATION
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.276-279
  • Anahtar Kelimeler: Liver flukes, Living-donor hepatectomy, Living-donor liver transplantation, Parasitic infection, CLONORCHIS-SINENSIS, TRANSPLANTATION, INFECTION, PROVINCE
  • İnönü Üniversitesi Adresli: Evet

Özet

The major advantage of preoperative magnetic resonance cholangiopancreatography is that living liver donor candidates with complicated biliary tracts may not be exposed to unnecessary laparotomy. To the best of our knowledge, the case presented here features a condition so far not seen by the Liver Transplantation Society. A 27-year-old woman who presented to our clinic as a living liver donor candidate was evaluated but did not have a preoperative magnetic resonance cholangiopancreatography due to technical factors. After parenchymal transection, the right hepatic duct was incised just distal to the bifurcation when 8 fasciola hepatica parasites left the orifice of the remnant bile duct. The common bile duct was then irrigated, and the remnant bile duct orifice was closed, followed by a cholangiography, which showed no suspicious lesions in the biliary tracts. In addition, no suspicious lesions were identified during the postoperative cholangiography of the graft implanted in the recipient. The donor and recipient had postoperative enzyme-linked immunosorbent assay immunoglobulin G antibody titers of 12 and 4 U/mL (cutoff value = 10) for fasciola hepatica, respectively. Both the recipient and the donor received 2 doses of triclabendazole (10 mg/kg) during the postoperative period.